All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network
The MPN Hub were pleased to speak to Ruben Mesa, University of Texas Health Science Center, San Antonio, US, during the 61st American Society of Hematology Meeting & Exposition in Orlando, US. We asked: Is fedratinib a safe and efficacious treatment option for patients with primary myelofibrosis and low platelet counts?
Ruben Mesa discusses two major studies that assessed fedratinib (JAK2 inhibitor) in patients with primary myelofibrosis; the randomized phase III trial JAKARTA study and the JAKARTA2 second-line study. He discusses the safety and efficacy of both trials.
Is fedratinib a safe and efficacious treatment option for patients with PMF and low platelet counts?
Is pacritinib safe and efficacious for patients with MF who failed ruxolitinib?
The MPN Hub were pleased to speak to Aaron Gerds, Cleveland Clinic Taussig Cancer Institute, Cleveland, US, during the 61st American Society of Hematology (ASH) meeting...
Dysregulation of the bone marrow niche contributes to the pathogenesis of myeloproliferative neoplasms
The bone marrow niche is the local tissue microenvironment that maintains and regulates stem cells for hematopoiesis. It is comprised of many...
Subscribe to get the best content related to MPN delivered to your inbox